# Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

> **NCT05914675** · PHASE4 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 21 (estimated)

## Conditions studied

- The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation

## Interventions

- **DRUG:** Letermovir

## Key facts

- **NCT ID:** NCT05914675
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914675, "Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05914675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*